Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL455691 | 0.90 | RAB9A (0.53) | SMN1; SMN2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL13162001 | 0.86 | NPC1 (0.55) | SMN1; SMN2CYP1A2CYP2C19NPC1RAB9A | |
| SCHEMBL13162870 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2NPC1RAB9AKDM1ATSHR | |
| SCHEMBL28481025 | 0.84 | MEN1 (0.51) | SMN1; SMN2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL2595672 | 0.83 | ALDH1A1 (0.51) | SMN1; SMN2NPC1RAB9AHPGDKDM1A | |
| SCHEMBL21619336 | 0.83 | RAB9A (0.46) | MEN1KMT2ANPC1RAB9AHPGD | |
| SCHEMBL13162026 | 0.83 | HPGD (0.56) | SMN1; SMN2KMT2ANPC1RAB9AHPGD | |
| SCHEMBL31495198 | 0.82 | KMT2A (0.52) | SMN1; SMN2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL13162687 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AKDM1ATSHR | |
| SCHEMBL13162029 | 0.81 | HPGDS (0.57) | SMN1; SMN2MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8754095-B2 | Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-06-17 | — | — | US | disclosed |
| US-8754095-B2 | Substituted N-heterocycloalkyl bipyrrolidinylphenyl amide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-06-17 | — | — | US | disclosed |
| EP-2569297-A1 | SUBSTITUTED N-HETEROCYCLOALKYL BIPYRROLIDINYLPHENYL AMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-20 | — | — | EP | disclosed |
| US-20130059891-A1 | SUBSTITUTED N-HETEROCYCLOALKYL BIPYRROLIDINYLPHENYL AMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | disclosed |
| US-20130059891-A1 | SUBSTITUTED N-HETEROCYCLOALKYL BIPYRROLIDINYLPHENYL AMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-07 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| WO-2011143161-A1 | SUBSTITUTED N-HETEROCYCLOALKYL BIPYRROLIDINYLPHENYL AMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143161-A1 | SUBSTITUTED N-HETEROCYCLOALKYL BIPYRROLIDINYLPHENYL AMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059891-A1 | SUBSTITUTED N-HETEROCYCLOALKYL BIPYRROLIDINYLPHENYL AMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | HRH3, HRH4, HRH1 | SMN1; SMN2 2407/4885MEN1 3792/4885CYP1A2 1276/4885 |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | TRPV1, FGFR3, GPR17 | SMN1; SMN2 3213/4885MEN1 4542/4885CYP1A2 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.